Cargando…

Non-Tuberculous Mycobacteria and Aspergillus Lung Co-Infection: Systematic Review

Non-tuberculous mycobacteria (NTM) and Aspergillus pulmonary co-infection occurs in patients with underlying lung disease and is rarely reported. We conducted a systematic search of NTM and Aspergillus pulmonary co-infection in PubMed, EMBASE, and Cochrane Library to identify cases published from 19...

Descripción completa

Detalles Bibliográficos
Autores principales: Fayos, Marina, Silva, Jose Tiago, López-Medrano, Francisco, Aguado, José María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571699/
https://www.ncbi.nlm.nih.gov/pubmed/36233487
http://dx.doi.org/10.3390/jcm11195619
_version_ 1784810427399536640
author Fayos, Marina
Silva, Jose Tiago
López-Medrano, Francisco
Aguado, José María
author_facet Fayos, Marina
Silva, Jose Tiago
López-Medrano, Francisco
Aguado, José María
author_sort Fayos, Marina
collection PubMed
description Non-tuberculous mycobacteria (NTM) and Aspergillus pulmonary co-infection occurs in patients with underlying lung disease and is rarely reported. We conducted a systematic search of NTM and Aspergillus pulmonary co-infection in PubMed, EMBASE, and Cochrane Library to identify cases published from 1977 to May 2022. We included 507 articles comprising 1538 cases (only 817 patients with partial relevant clinical data). Of these, 54.3% of patients were men, with a mean age of 57.7 years. Chronic obstructive pulmonary disease (21.1%), previous diagnosis of tuberculosis (18%), and asthma (11.1%) were the most common chronic lung diseases, and corticosteroids were used in 36.8% of patients. The most frequent symptoms were cough (68.2%), dyspnea (59.1%), and hemoptysis (34.1%). The most common radiological findings were bronchiectasis (52.3%) and cavitation (40.8%). NTM and Aspergillus were treated simultaneously in 47.3% of cases, whereas NTM-targeted therapy only was performed in 23.4% and Aspergillus only in 1.6%. The remaining 27.7% did not receive any treatment and were considered to be colonized. The global mortality rate was 43% (159/370). There was an increased prevalence of NTM and pulmonary aspergillosis among patients with underlying chronic lung diseases, which led to severe pulmonary affection with a poor global prognosis.
format Online
Article
Text
id pubmed-9571699
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95716992022-10-17 Non-Tuberculous Mycobacteria and Aspergillus Lung Co-Infection: Systematic Review Fayos, Marina Silva, Jose Tiago López-Medrano, Francisco Aguado, José María J Clin Med Review Non-tuberculous mycobacteria (NTM) and Aspergillus pulmonary co-infection occurs in patients with underlying lung disease and is rarely reported. We conducted a systematic search of NTM and Aspergillus pulmonary co-infection in PubMed, EMBASE, and Cochrane Library to identify cases published from 1977 to May 2022. We included 507 articles comprising 1538 cases (only 817 patients with partial relevant clinical data). Of these, 54.3% of patients were men, with a mean age of 57.7 years. Chronic obstructive pulmonary disease (21.1%), previous diagnosis of tuberculosis (18%), and asthma (11.1%) were the most common chronic lung diseases, and corticosteroids were used in 36.8% of patients. The most frequent symptoms were cough (68.2%), dyspnea (59.1%), and hemoptysis (34.1%). The most common radiological findings were bronchiectasis (52.3%) and cavitation (40.8%). NTM and Aspergillus were treated simultaneously in 47.3% of cases, whereas NTM-targeted therapy only was performed in 23.4% and Aspergillus only in 1.6%. The remaining 27.7% did not receive any treatment and were considered to be colonized. The global mortality rate was 43% (159/370). There was an increased prevalence of NTM and pulmonary aspergillosis among patients with underlying chronic lung diseases, which led to severe pulmonary affection with a poor global prognosis. MDPI 2022-09-23 /pmc/articles/PMC9571699/ /pubmed/36233487 http://dx.doi.org/10.3390/jcm11195619 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fayos, Marina
Silva, Jose Tiago
López-Medrano, Francisco
Aguado, José María
Non-Tuberculous Mycobacteria and Aspergillus Lung Co-Infection: Systematic Review
title Non-Tuberculous Mycobacteria and Aspergillus Lung Co-Infection: Systematic Review
title_full Non-Tuberculous Mycobacteria and Aspergillus Lung Co-Infection: Systematic Review
title_fullStr Non-Tuberculous Mycobacteria and Aspergillus Lung Co-Infection: Systematic Review
title_full_unstemmed Non-Tuberculous Mycobacteria and Aspergillus Lung Co-Infection: Systematic Review
title_short Non-Tuberculous Mycobacteria and Aspergillus Lung Co-Infection: Systematic Review
title_sort non-tuberculous mycobacteria and aspergillus lung co-infection: systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571699/
https://www.ncbi.nlm.nih.gov/pubmed/36233487
http://dx.doi.org/10.3390/jcm11195619
work_keys_str_mv AT fayosmarina nontuberculousmycobacteriaandaspergilluslungcoinfectionsystematicreview
AT silvajosetiago nontuberculousmycobacteriaandaspergilluslungcoinfectionsystematicreview
AT lopezmedranofrancisco nontuberculousmycobacteriaandaspergilluslungcoinfectionsystematicreview
AT aguadojosemaria nontuberculousmycobacteriaandaspergilluslungcoinfectionsystematicreview